What is TACE?
Transarterial Chemoembolization (TACE) is a minimally invasive, targeted treatment used primarily for liver cancer, particularly hepatocellular carcinoma (HCC). It combines chemotherapy with embolization to block the blood supply to the tumor, enhancing the effects of the chemotherapy drugs.
How Does TACE Work?
TACE involves the delivery of chemotherapy directly into the blood vessels feeding the tumor. The procedure is usually performed by an interventional radiologist. A catheter is inserted into the femoral artery and guided to the hepatic artery. Chemotherapy drugs are then delivered, followed by embolic agents that block the artery, trapping the chemotherapy in the tumor and cutting off its blood supply.
Who is a Candidate for TACE?
TACE is typically recommended for patients with intermediate-stage HCC who are not eligible for surgery or liver transplantation. It is also considered for patients with liver-dominant metastases from other cancers. Selection criteria include adequate liver function and performance status, as well as the absence of extrahepatic disease.
What are the Benefits of TACE?
TACE provides several benefits:
-
Localized Treatment: It delivers high concentrations of chemotherapy directly to the tumor, minimizing systemic exposure and side effects.
-
Tumor Shrinkage: It can reduce tumor size, potentially making tumors resectable or suitable for liver transplantation.
-
Palliative Care: It can alleviate symptoms and improve quality of life in patients with advanced cancer.
What are the Risks and Side Effects?
While TACE is generally safe, it is not without risks:
-
Post-embolization Syndrome: Commonly includes fever, pain, and nausea.
-
Liver Dysfunction: Potential for liver damage, especially in patients with compromised liver function.
-
Infection: Risk of infection at the catheter insertion site.
-
Non-target Embolization: Accidental blockage of non-tumor blood vessels.
How Effective is TACE?
The effectiveness of TACE varies based on several factors, including tumor size, location, and liver function. Studies show that TACE can significantly prolong survival in patients with intermediate-stage HCC. However, it is generally not curative and is often used in combination with other treatments such as
radiofrequency ablation or
systemic therapies.
What is the Procedure Like?
TACE is typically performed under local anesthesia with sedation. The procedure lasts 1-2 hours, and patients may need to stay in the hospital for monitoring post-procedure. Follow-up imaging is crucial to assess treatment response and plan further management.
What are the Alternatives to TACE?
Alternatives to TACE include:
-
Surgical Resection: For patients with resectable tumors.
-
Radiofrequency Ablation (RFA): For small tumors.
-
Systemic Therapy: Such as
sorafenib for advanced HCC.
-
Liver Transplantation: For eligible patients.
Conclusion
TACE is a valuable tool in the management of liver cancer, offering a targeted approach with the potential for significant benefits. However, patient selection is crucial, and understanding the risks and benefits can help optimize outcomes. Always consult with a multidisciplinary team to determine the best treatment strategy for individual cases.
